Goldenwell Biotech (GWLL) Common Equity (2019 - 2025)
Goldenwell Biotech's Common Equity history spans 7 years, with the latest figure at -$94823.0 for Q3 2025.
- For Q3 2025, Common Equity fell 592.87% year-over-year to -$94823.0; the TTM value through Sep 2025 reached -$94823.0, down 592.87%, while the annual FY2024 figure was -$47241.0, 155.76% down from the prior year.
- Common Equity reached -$94823.0 in Q3 2025 per GWLL's latest filing, down from -$86838.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $372594.0 in Q1 2021 to a low of -$94823.0 in Q3 2025.
- Average Common Equity over 5 years is $135183.3, with a median of $140929.0 recorded in 2023.
- Peak YoY movement for Common Equity: soared 48.11% in 2021, then crashed 2369.68% in 2025.
- A 5-year view of Common Equity shows it stood at $301713.0 in 2021, then crashed by 33.18% to $201618.0 in 2022, then tumbled by 57.98% to $84723.0 in 2023, then crashed by 155.76% to -$47241.0 in 2024, then crashed by 100.72% to -$94823.0 in 2025.
- Per Business Quant, the three most recent readings for GWLL's Common Equity are -$94823.0 (Q3 2025), -$86838.0 (Q2 2025), and -$81618.0 (Q1 2025).